Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Annual report 2017 (pdf):
download in single page format - double page (broad) format

Publication overview

Current news and events

Research at Oslo University Hospital basis for international drug development initiative between Norway and India

Kjetil Taskén (left) and Ivar Sjaastad
SERCA Pharmaceuticals AS, a company established by Inven2 AS in October, recently entered a co-development agreement with Cadila Pharmaceuticals - an FDA-approved Indian Pharma company with some 6000 employees. SERCA  Pharmaceuticals AS is established based on a drug development and innovation project on ischemia reperfusion injury in myocardial infarction that has been going on in the groups of Professors Kjetil Tasken (formerly NCMM UiO/OUH, now ICR, OUH) and Ivar Sjaastad (IEMF, OUH). The researchers have taken this forward to a drug candidate and have documented effects biochemically, in heart cells, by electrophysiology, on normal rat hearts and in rats with ischemia reperfusion injury where there is a cardioprotective effect.

Nature Biomedical Engineering publication:Study reveals how solid stress from brain tumors causes neuronal loss and neurologic dysfunction

Kyrre E, Emblem
Kyrre Eeg Emblem from the Department of Diagnostic Physics at OUS shares the first-authorship on a paper recently published in Nature Biomedical Engineering, entitled "Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium”. Using animal and human cancer data the authors show how solid stress – the physical forces exerted by the solid components of a tumor – impacts the tissue surrounding brain tumors and contributes to resulting neurological dysfunction and neuronal cell death. The authors also show how lithium treatment may protect against the effects of brain tissue compression.  


Research funding from South-Eastern Norway Regional Health Authority for 2019

The board of the South-Eastern Norway Regional Health Authority (Helse Sør-Øst) has distributed financial resources to new research projects for 2019. Of the in total 620 incoming applications 109 new projects were granted support.
A substantial amount of the resources goes to young researchers. Support is given to a number og doctoral and post doctoral stipendiates, as well as to researcher grants and career grants. The latter category is for young outstanding researchers planning to establish an independent research group.

Units and subpages

View all subunitsHide all subunits